Skeletal Muscle Differentiation kit now with control myoblasts
The new kit is designed to allow researchers to easily and consistently generate muscle from human pluripotent stem cells
13 Apr 2023
The Skeletal Muscle Differentiation kit from AMSBIO provides a unique protocol to differentiate human pluripotent stem cells to skeletal muscle with high yields and without cell sorting or genetic manipulation.
Now available with the option of simple-to-use control myoblasts, AMSBIO outlines how the kit offers stem cell researchers looking to differentiate stem cells to skeletal muscle with multinucleated myotubes produce consistent, high-quality results every time. Methods for studying muscular disease and potential therapies were, until recently, dependent on invasive muscle biopsies to produce limited batches of primary cells. Traditional use of primary cells presented challenges, not only in the collection process but also related to inconsistencies in cell growth, behavior and life span, making it difficult to generate dependable experimental models.
The AMSBIO Skeletal Muscle Differentiation kit has been designed to allow researchers to generate muscle from human pluripotent stem cells in three easy steps: via satellite-like or progenitor cells and myoblasts that then fuse to multinucleated myotubes in the third step. This method removes the need for time-consuming cell sorting or transfection of myogenic transcription factors. The Skeletal Muscle Differentiation kit protocol generates a highly pure population of approximately 70 percent skeletal muscle myotubes in a reproducible fashion.
